首页> 外文期刊>Neuropsychopharmacology >Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders|[quest]|
【24h】

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders|[quest]|

机译:氯胺酮:新型的情绪障碍疗法发展中的有前途的道路或错误的预言|

获取原文
           

摘要

Large ‘real world’ studies demonstrating the limited effectiveness and slow onset of clinical response associated with our existing antidepressant medications has highlighted the need for the development of new therapeutic strategies for major depression and other mood disorders. Yet, despite intense research efforts, the field has had little success in developing antidepressant treatments with fundamentally novel mechanisms of action over the past six decades, leaving the field wary and skeptical about any new developments. However, a series of relatively small proof-of-concept studies conducted over the last 15 years has gradually gained great interest by providing strong evidence that a unique, rapid onset of sustained, but still temporally limited, antidepressant effects can be achieved with a single administration of ketamine. We are now left with several questions regarding the true clinical meaningfulness of the findings and the mechanisms underlying the antidepressant action. In this Circumspectives piece, Dr Sanacora and Dr Schatzberg share their opinions on these issues and discuss paths to move the field forward.
机译:大型“现实世界”研究表明,与我们现有的抗抑郁药有关的有限的疗效和缓慢的临床反应发作,突显了开发针对重度抑郁症和其他情绪障碍的新治疗策略的必要性。然而,尽管进行了广泛的研究,但在过去的六十年中,该领域在开发具有根本新颖作用机制的抗抑郁药方面几乎没有成功,这使该领域对任何新进展持谨慎态度和怀疑态度。然而,在过去的15年中进行的一系列相对较小的概念验证研究,通过提供有力的证据证明,一次服用一种抗抑郁药具有独特,快速的持续,但仍有限的抗抑郁作用,就逐渐引起人们的极大兴趣。氯胺酮的管理。现在,我们对这些发现的真正临床意义以及抗抑郁作用的潜在机制尚存一些疑问。在此情况下,Sanacora博士和Schatzberg博士就这些问题分享了他们的观点,并讨论了推动该领域前进的途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号